Why the study?
Following the first ESC cardiomyopathy guidelines, this review explores multi-modality imaging advances to facilitate a personalized approach to patient care in HCM.
Multi-modality imaging is essential for the diagnosis, monitoring, and risk stratification of hypertrophic cardiomyopathy, facilitating a personalized approach to patient care.
Supports multi-modality imaging selection in HCM; reinforces ESC consensus while leaving optimal protocols open for prospective study.
Hypertrophic cardiomyopathy (HCM) is characterized by abnormal growth of the myocardium with myofilament disarray and myocardial hyper-contractility, leading to left ventricular hypertrophy and fibrosis. Where culprit genes are identified, they typically relate to cardiomyocyte sarcomere structure and function. Multi-modality imaging plays a crucial role in the diagnosis, monitoring, and risk stratification of HCM, as well as in screening those at risk. Following the recent publication of the first European Society of Cardiology (ESC) cardiomyopathy guidelines, we build on previous reviews and explore the roles of electrocardiography, echocardiography, cardiac magnetic resonance (CMR), cardiac computed tomography (CT), and nuclear imaging. We examine each modality's strengths along with their limitations in turn, and discuss how they can be used in isolation, or in combination, to facilitate a personalized approach to patient care, as well as providing key information and robust safety and efficacy evidence within new areas of research.
No takes yet. Share an insight, caveat, or question.
Goldie et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: